Catalogue > Proteasome > Alzheimer


Alzheimer

Ac-KLVFF-NH2 (70%) - Ac-KLVFF-NH2 (95%) - Amyloid-beta (1-40) human - Amyloid-beta (1-40) human (HCl-salt) - Amyloid-beta (1-40) rat - Amyloid-beta (1-40) rat (HCl-salt) - Biotinylated Amyloid-beta (1-40) human - Biotinylated Amyloid-beta (1-40) rat - Control peptide Amyloid-beta (40-1) human - Control peptide Amyloid-beta (40-1) rat - DWGKGGRWRLWPGASGKTEA (70%) - DWGKGGRWRLWPGASGKTEA (95%) - FYLKVPSSLHHHHGRDKLVFFHHHH (70%) - FYLKVPSSLHHHHGRDKLVFFHHHH (95%) - HNHKLVFFHHQH (70%) - HNHKLVFFHHQH (95%) - KLVFF (70%) - KLVFF (95%) - MOG (91-108) SDEGGYTCFFRDHSYQEE - NYSKMIFSHHHH (70%) - NYSKMIFSHHHH (95%) - PGRSPFTGKKLFNQEFSQDQ (70%) - PGRSPFTGKKLFNQEFSQDQ (95%) - qshyrhispaqv (D-amino acids) - RIIGL (70%) - RIIGL (95%)


Ac-KLVFF-NH2 (70%) 5 mg - P2256.7005
136,86 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



Ac-KLVFF-NH2 (95%) 1 mg - P2256.9501
136,86 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



Ac-KLVFF-NH2 (95%) 5 mg - P2256.9505
179,29 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



Amyloid-beta (1-40) human (HCl-salt) 1 mg - P2250.0001
343,73 EUR Package Size: 1 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Amyloid-beta (1-40) human (HCl-salt) 5 mg - P2250.0005
1.323,55 EUR Package Size: 5 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Amyloid-beta (1-40) human 1 mg - P2249.0001
207,94 EUR Package Size: 1 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Amyloid-beta (1-40) human 5 mg - P2249.0005
924,04 EUR Package Size: 5 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Amyloid-beta (1-40) rat (HCl-salt) 1 mg - P2248.0001
343,73 EUR Package Size: 1 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Amyloid-beta (1-40) rat (HCl-salt) 5 mg - P2248.0005
1.323,55 EUR Package Size: 5 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Amyloid-beta (1-40) rat 1 mg - P2247.0001
207,94 EUR Package Size: 1 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Amyloid-beta (1-40) rat 5 mg - P2247.0005
924,04 EUR Package Size: 5 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Biotinylated Amyloid-beta (1-40) human 1 mg - P2254.0001
406,85 EUR Package Size: 1 mg Biotinylated amyloid--peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid- peptides are



Biotinylated Amyloid-beta (1-40) human 5 mg - P2254.0005
1.436,85 EUR Package Size: 5 mg Biotinylated amyloid--peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid- peptides are



Biotinylated Amyloid-beta (1-40) rat 1 mg - P2253.0001
406,85 EUR Package Size: 1 mg Biotinylated amyloid--peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid- peptides are



Biotinylated Amyloid-beta (1-40) rat 5 mg - P2253.0005
1.436,85 EUR Package Size: 5 mg Biotinylated amyloid--peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid- peptides are



Control peptide Amyloid-beta (40-1) human 1 mg - P2252.0001
207,94 EUR Package Size: 1 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Control peptide Amyloid-beta (40-1) human 5 mg - P2252.0005
924,04 EUR Package Size: 5 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Control peptide Amyloid-beta (40-1) rat 1 mg - P2251.0001
207,94 EUR Package Size: 1 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



Control peptide Amyloid-beta (40-1) rat 5 mg - P2251.0005
924,04 EUR Package Size: 5 mg Amyloid--peptides: Characteristic of Alzheimer disease is the accumulation of amyloid plaques in the brain. The major components of these plaques are 39-42 residue-long amyloid--peptides, which form insoluble fibrils via self-assembly. The amyloid--peptides are fragments of the broadly distributed,



DWGKGGRWRLWPGASGKTEA (70%) 5 mg - P2258.7005
179,29 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



DWGKGGRWRLWPGASGKTEA (95%) 1 mg - P2258.9501
136,86 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



DWGKGGRWRLWPGASGKTEA (95%) 5 mg - P2258.9505
408,45 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



FYLKVPSSLHHHHGRDKLVFFHHHH (70%) 5 mg - P2261.7005
179,29 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



FYLKVPSSLHHHHGRDKLVFFHHHH (95%) 1 mg - P2261.9501
179,29 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



FYLKVPSSLHHHHGRDKLVFFHHHH (95%) 5 mg - P2261.9505
537,88 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



HNHKLVFFHHQH (70%) 5 mg - P2263.7005
136,86 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



HNHKLVFFHHQH (95%) 1 mg - P2263.9501
136,86 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



HNHKLVFFHHQH (95%) 5 mg - P2263.9505
408,45 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



KLVFF (70%) 5 mg - P2255.7005
136,86 EUR Package Size: 5 mg Biotinylated amyloid--peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid- peptides are



KLVFF (95%) 1 mg - P2255.9501
136,86 EUR Package Size: 1 mg Biotinylated amyloid--peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid- peptides are



KLVFF (95%) 5 mg - P2255.9505
179,29 EUR Package Size: 5 mg Biotinylated amyloid--peptides: Biotinylated peptides are a useful tool in many important applications. Biotin has a strong affinity for avidin or streptavidin. This interaction can be used for qualitative and quantitative detection, labelling or immobilisation. The biotinylated amyloid- peptides are



MOG (91-108) SDEGGYTCFFRDHSYQEE 1 mg - P2264.9501
136,86 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



MOG (91-108) SDEGGYTCFFRDHSYQEE 5 mg - P2264.7005
194,14 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



MOG (91-108) SDEGGYTCFFRDHSYQEE 5 mg - P2264.9505
387,23 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



NYSKMIFSHHHH (70%) 5 mg - P2262.7005
136,86 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



NYSKMIFSHHHH (95%) 1 mg - P2262.9501
136,86 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



NYSKMIFSHHHH (95%) 5 mg - P2262.9505
408,45 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



PGRSPFTGKKLFNQEFSQDQ (70%) 5 mg - P2259.7005
179,29 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



PGRSPFTGKKLFNQEFSQDQ (95%) 1 mg - P2259.9501
136,86 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



PGRSPFTGKKLFNQEFSQDQ (95%) 5 mg - P2259.9505
408,45 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



qshyrhispaqv (D-amino acids) 1 mg - P2260.9501
179,29 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



qshyrhispaqv (D-amino acids) 5 mg - P2260.9505
537,88 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



RIIGL (70%) 5 mg - P2257.7005
136,86 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



RIIGL (95%) 1 mg - P2257.9501
136,86 EUR Package Size: 1 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



RIIGL (95%) 5 mg - P2257.9505
179,29 EUR Package Size: 5 mg Several inhibitors of amyloid-beta aggregation have been published. Many of them are fragments and modified peptides derived from the native amyloid-beta sequence. Others were identified by phage display approaches. An overview about peptides that target amyloid-beta is described by Stains et al. (2007)



Show 1 to 45 (of in total 45 products) Sites:  1